Extendicare (TSE:EXE – Get Free Report) had its price objective raised by stock analysts at Royal Bank Of Canada from C$38.00 to C$39.00 in a report released on Friday,BayStreet.CA reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 18.83% from the company’s previous close.
Several other research analysts have also weighed in on the company. BMO Capital Markets increased their price objective on Extendicare from C$30.00 to C$38.00 in a research report on Wednesday, May 13th. Desjardins reduced their target price on Extendicare from C$40.00 to C$39.00 and set a “buy” rating on the stock in a research report on Monday. TD upped their price target on Extendicare from C$32.00 to C$39.00 and gave the company a “buy” rating in a research note on Monday, May 11th. National Bank Financial boosted their price objective on shares of Extendicare from C$34.00 to C$40.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Finally, Canaccord Genuity Group increased their target price on shares of Extendicare from C$37.00 to C$44.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of C$37.00.
Read Our Latest Analysis on EXE
Extendicare Trading Up 1.7%
Extendicare (TSE:EXE – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported C$0.32 earnings per share for the quarter. The business had revenue of C$611.04 million during the quarter. Extendicare had a net margin of 6.13% and a return on equity of 36.33%. On average, equities analysts anticipate that Extendicare will post 0.6134729 EPS for the current year.
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Read More
- Five stocks we like better than Extendicare
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
